Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Our mission is to target only diseases with significant unmet medical need and develop targeted, receptor-specific peptide therapeutics to provide safe and effective treatments to those in need.

Our vision is to become a successful global biopharmaceutical company through strategic partnerships and the development of new and innovative treatments for diseases with significant unmet medical need.

Palatin Technologies has received numerous awards, such as the Prism Award in 2010, the Edison Award in 2018, and the Ernst & Young Entrepreneur of The Year Award in 2018. The company has also been recognized as one of the top innovators in the pharmaceutical industry by industry publications.